How to Apply to Sartorius Stedim Biotech

10 min read Last updated April 20, 2026 13 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Sartorius Stedim Biotech is the French-listed (EPA: DIM) bioprocessing equipment subsidiary of Germany's Sartorius AG (FRA: SRT); CEO Rene Faber took over the group in 2025.
  • 2023-2024 was hard: post-COVID destocking cut revenue and the parent stock is down roughly 70% from its 2021 peak; recovery is real but uneven and worth discussing honestly in interviews.
  • Polyplus (acquired 2023 for approximately 2.4 billion euros) is the strategic bet on viral vector and gene therapy growth — relevant experience there is in high demand.
  • Main competitors are Cytiva (Danaher), Thermo Fisher, Merck KGaA Life Science, Repligen, Pall (Danaher), and Eppendorf — Sartorius is solidly number two globally in bioprocessing.
  • ATS is Workday at jobs.sartorius.com / sartorius.wd3.myworkdayjobs.com — invest in a clean candidate profile and review parsed fields after upload.
  • Culture is bilingual German-French with English as cross-functional working language; Goettingen is engineering-deep, Aubagne is commercial-operational, US sites operate more like standard US biotech.
  • BIOSECURE Act and GLP-1 manufacturing demand are the 2025-2026 tailwinds; cell/gene therapy commercialization is the longer-horizon bet.
  • European labor protections (CDI in France, IG BCE Tarifvertrag in Germany, Unite in UK) are real — pace yourself for longer hiring cycles and structured comp.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. (EPA: DIM) is the Aubagne, France-headquartered, French-listed bioprocessing equipment subsidiary of Germany's Sartorius AG (FRA: SRT, headquartered in Goettingen). Together the Sartorius Group employs roughly 14,000+ people globally; the Sartorius Stedim Bioprocess Solutions side accounts for approximately 10,000+ of those, with Lab Products & Services housed at the parent. CEO Rene Faber took over the Sartorius Group in 2025, replacing long-time chief Joachim Kreuzburg, who retired after building Sartorius into one of the two dominant Western bioprocessing equipment vendors alongside Cytiva (a Danaher subsidiary, formerly GE Healthcare Life Sciences). The Bioprocess Solutions division — what most people mean when they say 'Sartorius Stedim' — sells the picks-and-shovels of biopharma manufacturing: single-use bioreactors, cell culture media, fermentation systems, downstream processing (chromatography resins and skids, tangential-flow filtration, sterile filters), single-use bag and tubing assemblies with proprietary connectors, and process analytics. Customers manufacture monoclonal antibodies, vaccines, viral vectors, mRNA therapies, and increasingly cell and gene therapies. The customer roll includes Pfizer, Moderna, BioNTech, Lonza, Samsung Biologics, Catalent (now Novo Holdings-owned), Thermo Fisher Patheon, WuXi Biologics, and JSR Bio. Lab Products & Services covers analytical balances, pipettes, water purification, and bioanalytics platforms (Octet label-free binding, Incucyte live-cell imaging, Intellicyt flow cytometry). The honest 2024-2025 backdrop: Sartorius rode the COVID vaccine boom of 2020-2022 as Pfizer, Moderna, BioNTech, and CDMOs like Lonza, Samsung Biologics, and WuXi Biologics built out single-use bioreactor and filter capacity at unsustainable rates. 2023-2024 brought painful destocking — customers worked through inventory rather than reordering, and Sartorius Stedim revenue declined year-over-year. Sartorius AG stock is down roughly 70%+ from its 2021 peak. Recovery in 2024-2025 is real but uneven: GLP-1 manufacturing demand (Novo Nordisk, Eli Lilly), recovering biotech IPO funding, and commercial cell/gene therapy launches are restoring order books, while the 2024 BIOSECURE Act in the US — aimed at WuXi AppTec, BGI, and other Chinese biotechs — has become a quiet tailwind as Western pharma diversifies its CDMO and supplier base away from China. The strategic bet on the future is Polyplus, acquired in 2023 from Archimed PE for approximately 2.4 billion euros: viral vector and gene therapy plasmid manufacturing plus transfection reagents. Smaller deals (Claros, Novasep CGT Solutions) reinforce the cell and gene therapy positioning. None of this is guaranteed to recover the multiple — but it is the playbook.

Application Process

  1. 1
    Apply through jobs

    Apply through jobs.sartorius.com, which routes into the Workday ATS backend (sartorius.wd3.myworkdayjobs.com); filter by site (Goettingen, Aubagne, Stonehouse, Bohemia NY, Ann Arbor, Yauco PR, Bangalore, Singapore) and division (Bioprocess Solutions vs Lab Products & Services).

  2. 2
    Create a Workday candidate profile

    Create a Workday candidate profile — Workday remembers your data across Sartorius requisitions, so invest one careful pass uploading a clean CV plus parsed work history rather than fighting the parser on every application.

  3. 3
    For French sites (Aubagne, La Rochelle, Lourdes, Frettenheim) a French-language

    For French sites (Aubagne, La Rochelle, Lourdes, Frettenheim) a French-language CV plus French motivation letter is expected; CDI versus CDD status and French labor categorization (cadre vs non-cadre) will be discussed early.

  4. 4
    For German sites (Goettingen, Hamburg) a German Lebenslauf in tabular Europass-s

    For German sites (Goettingen, Hamburg) a German Lebenslauf in tabular Europass-style format with photo and Anschreiben is standard; expect to discuss IG BCE collective agreement coverage and Tarifvertrag wage band.

  5. 5
    For US sites (Bohemia NY for cell culture media, Ann Arbor MI for bioanalytics,

    For US sites (Bohemia NY for cell culture media, Ann Arbor MI for bioanalytics, Yauco Puerto Rico for filtration manufacturing) a standard one-to-two page US resume works; expect E-Verify and standard background checks.

  6. 6
    Recruiter screen (30 minutes by phone or Teams) covers motivation, language flue

    Recruiter screen (30 minutes by phone or Teams) covers motivation, language fluency, salary expectations in local currency, work authorization, and willingness to travel to customer sites or other Sartorius locations.

  7. 7
    Technical round with hiring manager: for R&D and process engineering expect deep

    Technical round with hiring manager: for R&D and process engineering expect deep questions on single-use bioreactor scale-up, cell culture media development, chromatography resin selection, sterile filtration validation, or whichever niche the role occupies.

  8. 8
    Panel or loop with cross-functional stakeholders

    Panel or loop with cross-functional stakeholders — at Sartorius this typically spans R&D, application science, product management, and a counterpart from the German or French sister site since most product lines are dual-sited.

  9. 9
    Final round may include a written case (process design problem, market analysis,

    Final round may include a written case (process design problem, market analysis, or customer technical proposal) plus a values and culture conversation with a senior leader; reference checks for senior roles are thorough.

  10. 10
    Offers reference local Tarifvertrag bands in Germany or French collective agreem

    Offers reference local Tarifvertrag bands in Germany or French collective agreements in France; equity participation exists for senior leaders but is modest compared to US biotech; long-term incentive plans are tied to Sartorius AG share performance, which has been volatile.

Resume Tips for Sartorius Stedim Biotech

recommended

Lead with the specific bioprocessing modality you know — upstream cell culture,

Lead with the specific bioprocessing modality you know — upstream cell culture, downstream purification, single-use systems, fill/finish, viral vector, mRNA, or cell therapy — Sartorius hires by deep technical lane, not generalist headcount.

recommended

Quantify scale: liters of bioreactor capacity, grams per liter titer, number of

Quantify scale: liters of bioreactor capacity, grams per liter titer, number of GMP batches supported, dollar value of single-use bag programs sold, square meters of filter area validated — vague 'led process improvements' resumes lose to specific ones.

recommended

Name the customer-side platforms you have worked with — Cytiva AKTA, Thermo HyCl

Name the customer-side platforms you have worked with — Cytiva AKTA, Thermo HyClone, Merck Mobius, Repligen XCell ATF, Pall Allegro — this signals you understand the competitive landscape Sartorius sells against and where their value proposition lands.

recommended

For application scientist and field roles, list the geographies and customer seg

For application scientist and field roles, list the geographies and customer segments you have covered (large pharma, CDMO, biotech, academic) and your fluency in technical sales motions including RFQ response and qualification protocols.

recommended

Cite regulatory frameworks you have operated under — EU GMP Annex 1 (sterile man

Cite regulatory frameworks you have operated under — EU GMP Annex 1 (sterile manufacturing), FDA 21 CFR 211, ICH Q7/Q9/Q10/Q11, USP 788 particulates, ISO 13485 — vague 'GMP experience' is weaker than specific framework citations.

recommended

Highlight any single-use systems extractables/leachables, BPOG protocol, or USP

Highlight any single-use systems extractables/leachables, BPOG protocol, or USP <1665> work — this is a recurring pain point for biopharma customers and Sartorius's value proposition leans heavily on documented compendial compliance.

recommended

For Polyplus / gene therapy roles, call out viral vector experience (AAV, lentiv

For Polyplus / gene therapy roles, call out viral vector experience (AAV, lentivirus), plasmid manufacturing, transfection reagent development, or HEK293/Sf9 production — this is where Sartorius is investing growth capital.

recommended

List languages honestly with CEFR levels (B2, C1, C2) — German for Goettingen ro

List languages honestly with CEFR levels (B2, C1, C2) — German for Goettingen roles, French for Aubagne roles, English for everything cross-functional; Mandarin or Japanese is a plus for Asia commercial roles.

recommended

Include any IG BCE, CFDT, CGT, or Unite union experience for European production

Include any IG BCE, CFDT, CGT, or Unite union experience for European production roles — works council (Betriebsrat / Comite Social et Economique) familiarity matters for plant leadership positions.

recommended

Skip generic skills sections; Workday parses content into structured fields, so

Skip generic skills sections; Workday parses content into structured fields, so make sure your job titles, dates, employers, and location strings are clean ASCII text rather than fancy graphics or PDF columns the parser will mangle.

ATS System: Workday

Sartorius runs Workday Recruiting, accessible at jobs.sartorius.com (which redirects into sartorius.wd3.myworkdayjobs.com). Workday is a structured-field parser that prefers clean, single-column resumes with explicit section headers. Once you create a candidate profile, your data persists across all Sartorius requisitions globally — so a careful first application pays dividends if you later apply to roles in Goettingen, Aubagne, or any US site.

  • Submit a single-column DOCX or text-based PDF (not image-based) so Workday's parser can extract job titles, dates, and employers into the structured candidate profile rather than dumping everything as free text.
  • Always review and correct the auto-parsed fields after upload — Workday gets dates and employer names wrong frequently, and recruiters search the structured fields, not the resume PDF.
  • Use standard section headers exactly: 'Work Experience,' 'Education,' 'Skills,' 'Certifications' — Workday's parser is tuned for these and will skip creative variants like 'My Journey' or 'Things I'm Good At.'
  • Format dates consistently as MM/YYYY or Month YYYY; mixed formats (2020-2022 alongside Jan 2023 - Present) confuse the parser and produce gaps that look like unemployment.
  • Apply to one role at a time per session — Workday timeouts cause partial applications to be lost, and the 'Save and Continue' button is the only reliable safety net.
  • Mirror the language of keywords in the requisition (single-use, downstream, chromatography, GMP, scale-up) without keyword-stuffing; Workday surfaces candidates whose parsed skills match the requisition's tagged competencies.

Interview Culture

Interview culture at Sartorius is shaped by the dual German-French DNA of the group.

Goettingen sets the engineering tone: deep, technical, evidence-driven, and unhurried. Expect to be asked to explain not just what you did but why, with first-principles reasoning about process design, mass transfer, scale-up math, or sterile filter validation. German hiring managers will press on technical depth and are not afraid of long silences while you think — fluent answers without substance fare worse than careful answers with reasoning shown. Aubagne and the French sites bring a more commercially-oriented, customer-facing energy: application scientist, field service, and product management roles will probe how you translate technical depth into customer outcomes. French interviews can feel more rhetorical and structured (problem, analysis, recommendation) and cadre-track candidates should be prepared for more abstract strategic questions in addition to operational ones. CDI versus CDD framing comes up early. US sites (Bohemia, Ann Arbor, Yauco) interview in a style closer to standard US biotech: behavioral STAR questions plus technical, with more emphasis on collaboration narratives and less on first-principles defense. Expect the typical American 'tell me about a time' loop alongside technical assessment. Across all sites, watch for honest questions about the 2023-2024 destocking cycle — Sartorius leaders know candidates have read the news, and pretending the COVID hangover never happened reads as poor diligence. Better to acknowledge the cycle, articulate the gene therapy / cell therapy / GLP-1 / BIOSECURE Act recovery thesis, and explain why you want to join the recovery rather than the boom. Politeness, technical seriousness, and a long-term mindset travel well.

What Sartorius Stedim Biotech Looks For

  • Deep technical specialization in a specific bioprocessing modality rather than generalist breadth — Sartorius sells specialized equipment and hires specialists who can credibly engage customer experts.
  • Evidence of customer empathy and field experience — engineers who have stood in a GMP suite or watched a customer process fail at 2,000 liters bring more value than pure bench scientists.
  • Comfort with European working culture: works councils, collective bargaining, longer decision cycles, multi-site coordination across time zones, and the German engineering norm of careful documentation.
  • Language fluency matched to site (German for Goettingen, French for Aubagne, English everywhere) plus willingness to learn the local language for long-term career growth.
  • Realism about the post-COVID bioprocessing cycle and a credible thesis on where the recovery comes from (GLP-1, cell/gene therapy, biosimilars, BIOSECURE Act-driven Western capacity buildout).
  • Familiarity with the competitive landscape — Cytiva, Thermo Fisher, Merck KGaA Life Science, Repligen, Pall, Eppendorf — and an honest read on where Sartorius wins and loses.
  • Regulatory literacy across EU GMP Annex 1, FDA 21 CFR 211, ICH guidelines, USP compendial standards, and ISO 13485 for medical-device-adjacent products.
  • Experience with single-use systems specifically (bags, connectors, extractables/leachables protocols, gamma irradiation validation) given Sartorius's strategic emphasis on disposables.
  • For Polyplus and gene therapy hires, viral vector experience (AAV, lentivirus), plasmid manufacturing, or transfection chemistry — this is the growth bet and the talent market is tight.
  • Long-term orientation rather than 18-month equity-flip mindset — Sartorius is a multi-decade family-influenced engineering company, not a venture-backed sprint.

Frequently Asked Questions

Is Sartorius Stedim Biotech the same company as Sartorius AG?
No, but they are tightly linked. Sartorius AG (FRA: SRT) is the German parent headquartered in Goettingen, with the Lab Products & Services division. Sartorius Stedim Biotech S.A. (EPA: DIM) is the separately French-listed subsidiary headquartered in Aubagne, France, holding the Bioprocess Solutions business. Sartorius AG owns the controlling stake in Sartorius Stedim Biotech, and the two are usually managed and reported as one group.
Who is the CEO and is leadership stable?
Rene Faber became CEO of the Sartorius Group in 2025, replacing Joachim Kreuzburg, who retired after a long tenure that built Sartorius into a global bioprocessing leader. The transition was planned and orderly, but Faber is inheriting a post-COVID destocking recovery and the integration of Polyplus, so leadership focus is on operational execution rather than radical strategic shifts.
How bad was the 2023-2024 bioprocessing destocking cycle?
Material. After the COVID vaccine boom drove Pfizer, Moderna, BioNTech, and CDMOs to over-order single-use bioreactors, filters, and cell culture media, customers spent 2023-2024 working through inventory rather than reordering. Sartorius Stedim revenue declined and the parent stock fell roughly 70% from its 2021 peak. Recovery is now underway in 2024-2025 but uneven — be prepared to discuss the cycle honestly in interviews rather than pretending it didn't happen.
What's the deal with Polyplus and the gene therapy bet?
Sartorius acquired Polyplus from Archimed PE in 2023 for approximately 2.4 billion euros. Polyplus makes transfection reagents and plasmids used in viral vector manufacturing for gene therapy and cell therapy. The strategic logic is that cell and gene therapy is the highest-growth segment of biopharma and Sartorius wanted upstream tooling exposure beyond traditional mAb bioprocessing. It is the most important growth bet in the portfolio, and gene therapy talent is being hired aggressively.
How does Sartorius compare to Cytiva and Thermo Fisher?
Cytiva (a Danaher subsidiary, formerly GE Healthcare Life Sciences, sold to Danaher in 2020 for 21 billion dollars) is the global number one in bioprocessing equipment and Sartorius's biggest competitor. Thermo Fisher is much larger overall but bioprocessing is one division among many, with Patheon adding CDMO services. Merck KGaA Life Science (MilliporeSigma in the US) is the third major Western competitor. Sartorius is solidly number two and competes on engineering depth, single-use innovation, and customer responsiveness.
What does the BIOSECURE Act mean for Sartorius hiring?
The 2024 BIOSECURE Act in the US restricts US biotechs and federal contractors from working with named Chinese suppliers like WuXi AppTec and BGI Genomics. The secondary effect is that Western pharma is diversifying CDMO and equipment supply chains, which benefits Sartorius, Cytiva, Lonza, Samsung Biologics, and other non-Chinese vendors. Hiring in US application science, field service, and CDMO-facing commercial roles has been steady on the back of this tailwind.
What's the working culture like across Goettingen, Aubagne, and US sites?
Goettingen is German engineering culture: deep technical, careful documentation, longer decision cycles, IG BCE union and Betriebsrat works council. Aubagne is French biopharma operational culture: more commercially-oriented, CDI-protected, with CFDT/CGT unions and a Comite Social et Economique. US sites (Bohemia NY for cell culture media, Ann Arbor MI for bioanalytics, Yauco PR for filtration manufacturing) operate more like standard US biotech. English is the cross-functional working language across the group.
Is now a good time to join given the stock decline?
Honest answer: it depends on your time horizon. The Sartorius AG stock is down roughly 70% from its 2021 peak and long-term incentive plans tied to share price have been painful for recent joiners. If you want to join the recovery and believe in the gene therapy / GLP-1 / BIOSECURE Act thesis, valuations are arguably attractive entry points. If you're comparing against a venture-backed biotech with fresh equity and rapid upside, Sartorius is a slower, more stable bet — better for craft and career, less for near-term wealth creation.
What languages do I need?
For Goettingen and other German sites, German (B2 or higher) is strongly preferred and often required for production and operations roles; English-only is workable in some R&D and global roles. For Aubagne and other French sites, French (B2 or higher) is required for most non-management roles. For US sites, English suffices. For Asia commercial roles (Singapore, Tokyo, Shanghai), Mandarin or Japanese is a strong plus. English is the cross-functional working language across the group.
How long is the hiring process?
Typically 6 to 10 weeks for engineering and scientist roles, longer for senior leadership. European labor protections (CDI in France, Tarifvertrag in Germany) extend the back end as offers wind through HR, works council notification, and final approvals. Don't be surprised by 2 to 3 weeks of silence between rounds — it is often process, not lack of interest.
Are there remote or hybrid roles?
Most R&D, manufacturing, application science, and product management roles are site-based or hybrid (typically 3 days on-site). Commercial roles (sales, business development, field application) are field-based with regional travel. Fully remote is rare and typically reserved for specialist roles like regulatory affairs or specific software engineering positions. Be honest about your geographic constraints early in the recruiter screen.
What's the equity / long-term incentive picture?
Sartorius offers long-term incentive plans tied to Sartorius AG (FRA: SRT) share performance for senior roles. The plans are modest by US biotech standards and have been volatile given the stock's decline from 2021 peaks. Cash compensation in Germany follows IG BCE Tarifvertrag bands; in France, cadre versus non-cadre status and CDI protections shape comp. US sites pay closer to market US biotech ranges. For early career and individual contributor roles, equity is minimal — focus negotiation on base, bonus, and benefits.

Open Positions

Sartorius Stedim Biotech currently has 13 open positions.

Check Your Resume Before Applying → View 13 open positions at Sartorius Stedim Biotech

Related Resources

Similar Companies

Related Articles

Sources

  1. Sartorius Group Investor Relations —
  2. Sartorius Stedim Biotech S.A. (EPA: DIM) Investor Page —
  3. Sartorius Careers Portal —
  4. Sartorius Acquires Polyplus for 2.4B Euros (Press Release) —
  5. Rene Faber Appointed CEO of Sartorius Group (2025) —
  6. BIOSECURE Act Overview (US Congress) —
  7. Cytiva (Danaher) Bioprocessing Overview —
  8. Thermo Fisher Bioproduction Division —
  9. Merck KGaA Life Science (MilliporeSigma) —
  10. Repligen Corporation (NASDAQ: RGEN) —
  11. EU GMP Annex 1 Sterile Manufacturing Guidance —
  12. IG BCE (German Mining, Chemical, Energy Industrial Union) —
  13. Workday Candidate Help Center —